Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment
Our increased understanding of tumour biology gained over the last few years has led to the development of targeted molecular therapies, e.g., vascular endothelial growth factor A (VEGF-A) antagonists, poly[ADP-ribose] polymerase 1 (PARP1) inhibitors in hereditary breast and ovarian cancer syndrome...
Main Authors: | Katarzyna M. Terlikowska, Bożena Dobrzycka, Sławomir J. Terlikowski |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/7/3495 |
Similar Items
-
Chimeric antigen receptor T-cell therapy for T-ALL and AML
by: Wenwen Wei, et al.
Published: (2022-11-01) -
Chimeric Antigen Receptor T Cell Therapy in Hematology
by: Pınar Ataca, et al.
Published: (2015-11-01) -
Chimeric antigen receptors that trigger phagocytosis
by: Meghan A Morrissey, et al.
Published: (2018-06-01) -
NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44
by: Rüdiger Klapdor, et al.
Published: (2021-09-01) -
CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
by: Alankrita Taneja, et al.
Published: (2022-01-01)